Metabolic profiling reveals interleukin-17A monoclonal antibody treatment ameliorate lipids metabolism with the potentiality to reduce cardiovascular risk in psoriasis patients

BACKGROUND: Psoriasis is a common chronic inflammatory skin disease associated with overproduction of interleukin-17A (IL-17A). IL-17A monoclonal antibodies (mAbs) have shown clinical efficacy in psoriasis patients. Although a series of different overlapping mechanisms have been found to establish a...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Han, Su, Shengmin, Yang, Qi, Le, Yunchen, Chen, Lihong, Hu, Mengyan, Guo, Xiaoyu, Zheng, Jie, Li, Xia, Yu, Yunqiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890626/
https://www.ncbi.nlm.nih.gov/pubmed/33602246
http://dx.doi.org/10.1186/s12944-021-01441-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890626/
https://www.ncbi.nlm.nih.gov/pubmed/33602246
http://dx.doi.org/10.1186/s12944-021-01441-9

Ejemplares similares